FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

U.S. FDA — The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose.

Read the original at U.S. FDA ↗

Auto-published by the finit.news Events monitor from U.S. FDA; summarized by AI and may contain errors — verify against the primary source. July 18, 2026.